Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-13, Stock:NVO, The news for the past five days is as follows:
2018-02-06: NEWS1: Novo Nordisk's Dichotomy Abounds.NEWS2: Novo Nordisk's Dichotomy Abounds.NEWS3: Novo Nordisk&apos;s Dichotomy Abounds.NEWS4: FOCUS-In diabetes war, Novo Nordisk aims to break mould with new pill.NEWS5: Analysts’ Recommendations for Novartis after Its 4Q17 Earnings.
2018-02-07: NEWS1: Sanofi Leads the Hemophilia Space on Bioverativ Acquisition.
2018-02-08: NEWS1: A Look at Ablynx and Sanofi’s Existing Partnership.NEWS2: Highlights of Sanofi’s 3.9 Billion Euro Ablynx Acquisition.NEWS3: Analysts’ Updates after Sanofi’s Bioverativ Announcement.
2018-02-09: nan
2018-02-12: NEWS1: Health Care Sector Update for 02/12/2018: AXON,UTHR,NVO,FOLD,AVEO.NEWS2: Health Care Sector Update for 02/12/2018: AXON,UTHR,NVO,FOLD,AVEO.NEWS3: Noteworthy ETF Outflows: VEU, TD, SAP, NVO.NEWS4: Noteworthy ETF Outflows: VEU, TD, SAP, NVO.NEWS5: Blog Exposure - Novo Nordisk’s Ozempic is Approved in the EU for the Treatment of Type 2 Diabetes.NEWS6: GlaxoSmithKline plc -- Moody's: M&A greatest downside risk to European pharma companies' credit quality in 2018.NEWS7: Better Buy: Pfizer Inc. (PFE) vs. Eli Lilly (LLY).NEWS8: Better Buy: Pfizer Inc. (PFE) vs. Eli Lilly (LLY).

Answer: Decrease